Earnings calls

Natco Pharma concall ledger

Every earnings call for NATCOPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.

NATCOPHARM · 6 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 12 Feb 2026Call held 12 Feb 2026

NATCOPHARM Q3 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹705.4 cr+8% YoYEBITDA₹216.8 crEBITDA Margin30.7%Consolidated Net Profit₹151.3 cr

Consolidated Revenue ₹705 cr (+8% YoY); EBITDA ₹217 cr; EBITDA Margin 30.7%. Consolidated revenue of ₹705.4 crores, up 8.34% YoY.

Q2 FY26Published 14 Nov 2025Call held 14 Nov 2025

Consolidated total revenue for Q2 FY26 was Rs 1,463 crores, up from Rs 1,434.9 crores in Q2 FY25.

Q1 FY26Published 13 Aug 2025Call held 13 Aug 2025

Consolidated total revenue for Q1 FY26 was INR1,390.6 crores, a slight decline from INR1,410.7 crores in Q1 FY25.

Q4 FY25Published 23 Jul 2025Call held 23 Jul 2025

Natco Pharma proposes to acquire a 35.75% stake in Adcock Ingram Holdings Limited.

Q3 FY25Published 13 Feb 2025Call held 13 Feb 2025

Consolidated total revenue for Q3 FY25 was ₹651.1 crores, down from ₹795.6 crores in Q3 FY24, representing an 18.16% YoY decline.

Q2 FY25Published 13 Nov 2024Call held 13 Nov 2024

Consolidated total revenue of INR1,434.9 crores, up 35.3% YoY.